New Delhi, 22 July 2024: The Indian Patent Office’s rejection of Johnson & Johnson’s (J&J) application for the paediatric version of its anti-tuberculosis (TB) drug, bedaquiline, is likely to have broader implications for access to cost-effective TB treatment,......
View Details

Related News

• UK regulator probes anti-depressants safety alerts after suicide link (12-12-2024)

---

• Haryana Food Department to Crack Down on Fake Protein Supplements After Major Bust (12-12-2024)

---

• Drug inspector sentenced to 3-yr rigorous imprisonment (12-12-2024)

---

• 11.12 crore worth of short-shelf life medicines expired due to delayed supply to TNMSC: CAG Report (12-12-2024)

---

• Ayush Ministry amends D&C Act to add Homoeopathy, Sowa Rigpa books and Pharmacopoeias (12-12-2024)

---

• Construction of all three bulk drug parks are in progress: Ministry of chemicals (12-12-2024)

---

• Four-member gang nabbed for selling ‘Mephentermine Sulphate’ injections in Hyderabad (12-12-2024)

---

• Combining BCL-2 and BTK inhibitors shows promise in chronic lymphocytic leukemia (CLL) (11-12-2024)

---

• Punjab cop arrests man for narcotic drugs case, gets fined by court (11-12-2024)

---

• NPPA Mandates Transparency in Angioplasty Billing with Separate Costs for Non-Stent Components: MoS Anupriya Patel (11-12-2024)

---